Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ICWIP trial (icotinib): what clinicians have said so far
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
- NCT02125240 ↗
- Unknown
- Betta Pharmaceuticals Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ICWIP (icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ICWIP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma
- Interventions
- Icotinib; Placebo
- Arms
- Icotinib · Experimental
- Placebo · Active comparator
- Enrollment
- 124 (estimated)
- Primary outcomes
- Disease-free survival
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Dec 2018 (estimated)
- Results posted
- No
- Registry record
- NCT02125240 · updated Jul 16, 2018
Publications
linked from the registry- Liu YT, Tang L, Han XH, Song ZY, Liu DR, Cheng G, Xiao WH, Zhang SC, Hu Y, Zhang L, Liu JF, Wang J, Dong GL, Shi YK. Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. Signal Transduct Target Ther. 2026 Aug 28;11(1):354. doi: 10.1038/s41392-026-02994-w. PubMed 42660909
- Liu YT, Hao XZ, Liu DR, Cheng G, Zhang SC, Xiao WH, Hu Y, Liu JF, He M, Ding CM, Zhang L, Wang J, Li H, Dong GL, Zhi XY, Li J, Shi YK. Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial. Cancer Manag Res. 2020 Jun 17;12:4633-4643. doi: 10.2147/CMAR.S240275. eCollection 2020. PubMed 32606956